Interleukin-6 receptor blockade for the treatment of NMOSD

Affiliations

Comment

Michael Levy. Lancet Neurol. 2020 May.

. 2020 May;19(5):370-371.

doi: 10.1016/S1474-4422(20)30081-8.

¹ Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: mlevy11@mgh.harvard.edu.

No abstract available

Comment on

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Traboulsee A, et al. Lancet Neurol. 2020 May;19(5):402-412. doi: 10.1016/S1474-4422(20)30078-8. Lancet Neurol. 2020. PMID: 32333898 Free PMC article. Clinical Trial.